Skip to main content Skip to search Skip to main navigation
Question of the Week | GMP-Verlag

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

Components in the airflow path, such as filling needles, laminarisators, and sensors, must be aerodynamically designed, sterile, and particle-free to avoid disrupting First Air. While some airflow interruptions are unavoidable, these must not compromise the protective airflow or cause turbulence that could introduce contaminants.

[GMP Compliance Adviser, Chapter  First Air: Core Aerodynamic Barrier for Aseptic Processes ]

Would you like to discover more?

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The free demo access is non-binding and ends automatically after 7 days.

Test it now for free

You may also be interested in the following articles:

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
News: EMA

EMA: Report on First Bilateral Meeting with APIC Published

The EMA has published the highlights of its first bilateral meeting with the Active Pharmaceutical Ingredients Committee (APIC). Topics included GMP oversight of API manufacturers, the reuse of recovered solvents and nitrosamine risks.
Read more
Save Time and Money when Qualifying a Blister Packaging Line

Save Time and Money when Qualifying a Blister Packaging Line

Qualifying a blister packaging line is not only technically demanding, but also time-consuming and costly. Here you will find important tips on how to organise your qualification process in a cost-effective yet gmp-compliant manner.

Read more
Previous
Next